Xiuning Le, Associate Professor at MD Anderson Cancer Center, shared a post on LinkedIn:
“Honored to present at SITC2025 the final overall survival (OS) results of HARMONi-A study: ivonescimab + carbo/pem in TKI-refractory EGFR-mutant NSCLC mdanderson
- OS HR 0.74 (0.58-0.95), p = 0.019
- Pronounced benefit in patients with brain metastases (HR 0.61)
- This regimen has been approved in China
- We continue to reshape the therapeutic landscape with immunotherapies
- Photo courtesy to Zhen Su, MD MBA (Marengo CEO).”
